All Photos(3)

Documents

O5015

Oxybutynin chloride

Name: Oxybutynin chloride
Brand: SIAL

meets EP, USP testing specifications

Synonym(s):

α-Phenylcyclohexaneglycolic acid 4-(diethylamino)-2-butynyl ester hydrochloride

Sign Into View Organizational & Contract Pricing

All Photos(3)

About This Item

Empirical Formula (Hill Notation):

C₂₂H₃₁NO₃ · HCl

CAS Number:

1508-65-2

Molecular Weight:

393.95

EC Number:

216-139-7

MDL number:

MFCD00072150

UNSPSC Code:

12161900

PubChem Substance ID:

24898008

NACRES:

NA.21

Agency

USP/NF
meets EP testing specifications
meets USP testing specifications

Quality Level

200

form

solid

application(s)

pharmaceutical (small molecule)

storage temp.

room temp

SMILES string

Cl.CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2

InChI

1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H

InChI key

SWIJYDAEGSIQPZ-UHFFFAOYSA-N

Gene Information

human ... CHRM2(1129) , CHRM3(1131)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Detergents - Anionic, Cationic, Zwitterionic, Anti-foaming

Biochem/physiol Actions

Muscarinic acetylcholine receptor antagonist; inhibits proliferation of bladder smooth muscle cells, perhaps by downregulation of growth promoting genes.

Pictograms

GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.

Naoki Aizawa et al.

European urology, 62(6), 1165-1173 (2012-09-18)

Mirabegron is the first β3-adrenoceptor agonist that is clinically effective for overactive bladder. The effects of mirabegron on primary bladder mechanosensitive single-unit afferent activities (SAAs) and bladder microcontractions were evaluated and compared with the effects of oxybutynin. Female Sprague-Dawley rats

P Tauzin-Fin et al.

Annales francaises d'anesthesie et de reanimation, 31(7-8), 605-608 (2012-07-04)

Catheter-related bladder discomfort (CRBD) is an unrecognized clinical event. Symptoms of CRBD secondary to an indwelling urinary catheter mimic those of an overactive bladder, i.e. urinary frequency and urgency with or without urge incontinence. Stimulation of muscarinic receptors located in

Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia.

Theodore M Johnson et al.

BJU international, 112(1), 100-108 (2013-03-02)

WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: Nocturia is a common and bothersome lower urinary tract symptom, particularly in men. Many single drug therapies have limited benefit. For men who have persistent nocturia despite alpha-blocker therapy

Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.

Michael H Johnson et al.

The Journal of urology, 189(4), 1268-1274 (2012-11-06)

Intravesical bacillus Calmette-Guérin is used to decrease recurrence rates of nonmuscle invasive urothelial carcinoma. Irritative urinary symptoms are a common side effect of treatment and frequently limit treatment tolerance. While anticholinergic medications may be used for symptom prophylaxis, to our

Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves.

Jessica T Casey et al.

The Journal of urology, 188(4 Suppl), 1516-1520 (2012-08-23)

Abnormal bladder function following posterior urethral valve ablation can lead to deleterious effects on renal function and urinary continence. We performed a pilot study to determine if bladder dysfunction could be ameliorated by the early administration of oxybutynin. We enrolled

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service